Journals / Eurasian Journal of Medicine / 2019 / Cilt: 51 - Sayı: 3

Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome

Pages
280–284
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Considering the effects of nesfatin-1, it may be associated with metabolic syndrome.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Metabolic syndrome is associated with a group of conditions abdominal obesity, high triglyceride levels, reduction in low-density lipoprotein, increased blood pressure, and increased fasting blood glucose.
📊
Key Findings & Data:Hence, it poses a risk for type 2 diabetes and cardiovascular diseases.
💡
Conclusion & Impact:Considering the effects of nesfatin-1, it may be associated with metabolic syndrome.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Metabolic syndrome is associated with a group of conditions abdominal obesity, high triglyceride levels, reduction in low-density lipoprotein, increased blood pressure, and increased fasting blood glucose. Hence, it poses a risk for type 2 diabetes and cardiovascular diseases. The prevalence of metabolic syndrome increases with age. Nesfatin-1, which affects different systems, has recently been discovered as a regulatory peptide molecule. With the discovery of nesfatin-1, it has been reported to inhibit the intake of nutrients and have significant regulatory effects on energy metabolism. As nesfatin-1 is present in both central and peripheral tissues, it is thought to have many functions. In addition to its suppressive effect on food intake, nesfatin-1 has also been reported to have an effect on the blood glucose level for regulating cardiac functions and affecting obesity by providing weight loss. Considering the effects of nesfatin-1, it may be associated with metabolic syndrome.

🔖

Cite This Article

TEKİN, T., ÇİÇEK, B., KONYALIGİL, N. (2022). Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. Eurasian Journal of Medicine, Cilt: 51 - Sayı: 3, 280–284. https://ajindex.com/articles/508929

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Koç F, Tokaç M, Kocabaş V, et al. Ghrelin, Resistin and Leptin Levels in Patients with Metabolic Syndrome. Eur J Gen Med 2011
  2. [CrossRef] 2. Kim SR, Lehman LO. Diagnostic imaging in the management of patients with metabolic syndrome. Transl Res 2018
  3. [CrossRef] 3. Turkish Endocrinology and Metabolism Association, The Metabolic Syndrome Guide, 2009 (in Turkish). Date of Access: 12.03.2018 4. Mirzaei K, Nezhad AH, Keshavarz SA, et al. Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects. Diabetol Metab Syndr 2013
  4. [CrossRef] 5. Abaci A, Catli G, Anik A, Kume T, Bober E. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes 2013
  5. [CrossRef] 6. Algül S, Özçelik O. Determination of the Effects of Acute Aerobic Exercise on Nesfatin-1 Levels. Fırat University Medical Journal of Health Sciences. 2016
  6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002
  7. [CrossRef] 8. Alexander CA. The coming of age of the metabolic syndrome. Diabetes Care 2003
  8. [CrossRef] 9. Altuntaş Y. Metabolic syndrome and insulin resistance. Metabolic Syndrome Yearbook. Metabolic Syndrome Association. Ayrıntı Printing House, Ankara, 2009. 10. Grundy SM, Brewer Jr HB, Cleeman JI. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004
  9. [CrossRef] 11. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006
  10. [CrossRef] 12. Stengel A, Tache Y. Nesfatin-1--An Emerging New Player in the Brain-Gut, Endocrine, and Metabolic Axis. Endocrinology 2011
  11. [CrossRef] 13. Aydın S. Multi-functional peptide hormone NUCB2/nesfatin-1. Endocrine 2013
  12. [CrossRef] 14. García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M. Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J Mol Endocrinol 2010
  13. [CrossRef] 15. Stengel A. Nesfatin-1 - More than a food intake regulatory peptide. Peptides 2015
  14. [CrossRef] 16. Shimizu H, Oh-I S, Hashimoto K, et al. Peripheral Administration of Nesfatin-1 Reduces Food In